Souhaitez-vous accéder aux communiqués récents ?

Examines the evolving competitive landscape, regulatory developments & investment trends shaping the future of chronic kidney disease management worldwide.

Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of...

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end...

Dublin, July 06, 2026 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Rheumatology KOLs - United States" has been added to ResearchAndMarkets.com's offering. The Thought...

VERAXA Biotech announces further progress with lead BiTAC® T-cell engager (BiTAC-TCE) program, initiates cell line development with ATUM.

Anaveon appoints Laetitia Pouzol as Chief Scientific Officer.

New analyses from the Phase 3 Vivacity-MG3 study support the impact of nipocalimab in anti-AChR+a, anti-MuSK+b adult patients with generalised myasthenia gravis (gMG) including those early in their...

BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data...

Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage...

Austin, TX, USA, June 24, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Density Gradient Media Market Size, Trends and Insights By Product (Sodium...